perhaps a deal this year is unrealistic, August is the CDP and give 6 months minimum after that just for the paperwork / negotiations.
Perhaps more likely after we see some P2 data for cardio protect so they can actually show it works.
There is a big gap in value if Zantrene is itself cardio safe, v protects against cardiotoxicity of other drugs +
anti cancer effect.
We only have in vitro and historical data on adverse events, so not ideal for approaching Pharma for a deal if we want big bucks.
Sounds familiar ?, page-9
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
